Company Intelligence
FinalDose
FinalDose provides enterprise-grade artificial intelligence solutions, delivering specialized Programmable DNA drug destroying all cancers, unlocking 80% of targets technology designed to optimize mission-critical workflows across enterprise software developers and digital transformation teams.
- Headquarters
- London, United Kingdom
- Website
- finaldose.ai
- Founded
- 2026
- Employees
- 5
- Stage
- Early
- Status
- Active
- Products
- 1
- Reports
- 8
- Last reviewed
- Aug 2026
Overview
What this company is, what it builds, and who it serves.
FinalDose is a Healthcare AI company based in London, United Kingdom, founded in 2026.
FinalDose develops programmable DNA drug destroying all cancers, unlocking 80% of targets.
What it builds
Programmable DNA drug destroying all cancers, unlocking 80% of targets
Why It Matters
FinalDose provides enterprise-grade artificial intelligence solutions, delivering specialized Programmable DNA drug destroying all cancers, unlocking 80% of targets technology designed to optimize mission-critical workflows across enterprise software developers and digital transformation teams.
Products
Products and platforms connected to this company.
-
FinalDose
Explore FinalDose by FinalDose. Verified AI product intelligence covering core capabilities, Healthcare use cases, technical architecture, and FAQs.
View product intelligence
Ecosystem
How this company connects across the Brel AI intelligence graph.
Company
FinalDose
Industry
Products
Capabilities
- Programmable DNA drug destroying all cancers, unlocking 80% of targets
Features
- Programmable DNA drug destroying all cancers, unlocking 80% of targets
Country
Official Resources
Official and developer links on file for this company.
Frequently Asked Questions
What does FinalDose do?
FinalDose specializes in artificial intelligence, developing Programmable DNA drug destroying all cancers, unlocking 80% of targets to support enterprise software developers and digital transformation teams with scalable, production-grade technology.
Where is FinalDose based and when was it founded?
FinalDose is based in United Kingdom and was founded in 2026.
What are the main products offered by FinalDose?
The flagship platform from FinalDose is Programmable DNA drug destroying all cancers, unlocking 80% of targets, delivered primarily through b2b saas and enterprise api licensing.
Who are the primary target users of FinalDose?
FinalDose primarily serves enterprise software developers and digital transformation teams seeking reliable artificial intelligence implementations.
Sources & Verification
How this profile is verified and where the information comes from.
Primary sources
Request a correction if you represent this company or believe information is inaccurate.